Trump Cannabis Rescheduling Falls Short of Industry Tax Expectations
Federal rescheduling under Trump administration would provide minimal 280E relief, leaving cannabis operators facing continued tax burdens despite regulatory progress.
The cannabis industry's hopes for substantial tax relief under potential Trump administration rescheduling face a harsh reality check. While moving cannabis from Schedule I to Schedule III would mark historic regulatory progress, the financial impact on operators remains far more limited than many investors anticipate.
Section 280E of the tax code, which prevents cannabis businesses from deducting standard operating expenses, would only see partial relief under rescheduling. Schedule III substances still face federal tax restrictions, meaning multi-state operators like Curaleaf (CURLF), Trulieve (TCNNF), and Green Thumb Industries (GTBIF) would continue shouldering effective tax rates exceeding 70% in many cases. The industry's $1.8 billion annual tax burden would shrink modestly, not disappear.
This tax reality creates a disconnect between political momentum and financial fundamentals. Cannabis stocks have rallied on rescheduling optimism throughout 2024, with the AdvisorShares Pure US Cannabis ETF (MSOS) gaining over 45% since October lows. However, operators would still face competitive disadvantages against traditional retail and consumer goods companies that enjoy full tax deductibility.
The limited tax relief also complicates capital allocation strategies for cannabis companies already struggling with profitability. Major operators have delayed expansion plans and reduced cultivation capacity due to pricing pressures and regulatory costs. Rescheduling without comprehensive tax reform leaves these operational challenges largely intact, potentially disappointing investors expecting transformational financial improvements.
Industry stakeholders now pivot toward advocating for complete federal legalization rather than incremental scheduling changes. The SAFE Banking Act and comprehensive reform legislation gain renewed importance as rescheduling proves insufficient for addressing cannabis companies' core financial obstacles. Operators must continue navigating punitive tax structures while competing in increasingly saturated state markets, regardless of federal scheduling status.